Pietro Pignatta

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

M. Gangitano, F. Ferreri, M. Tombini, 2022, Seizure.

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

M. Gangitano, F. Ferreri, M. Tombini, 2022, Drugs & Aging.

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

M. Gangitano, F. Ferreri, M. Tombini, 2021, CNS Drugs.

Clinical predictors of response to adjunctive brivaracetam: Insights from real‐world data

S. Lattanzi, C. Di Bonaventura, E. Ferlazzo, 2021, Epilepsia.

Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry

S. Kochen, A. Carius, B. Steinhoff, 2018, The Lancet Neurology.

Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Ewout J. N. Groen, Annelot M. Dekker, Ross P. Byrne, 2021, Nature Genetics.

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

M. Gangitano, F. Ferreri, M. Tombini, 2022, Neurology and Therapy.